Evaluation of Closed-loop TIVA Propofol, Sufentanil and Ketamine Guided by BIS Monitor

Recent efforts have focused on the development of new software systems that are able to
directly titrate anesthesia based on activity of the brain (EEG) as a feedback mechanism .
Brain activity is used to measure the effect of anesthetic medications (anesthetic "depth"),
which can vary from person to person despite being given the same amount of medication.
There is a potential for new systems to considerably improve anesthetic control by using
methods that are able to adapt to the constant input of brain activity. The purpose of this
study is to compare a closed -loop intravenous anesthetic (TIVA) using BIS (Bispectral
Index) as a feedback loop and a controller based on reinforcement learning to titrate dose
and TIVA that is manually controlled or a standard volatile anesthetic agent titrated by the
anesthesiologist.

Propofol is the most frequently applied hypnotic-anesthetic IV drug during anesthesia. In
"open-loop" controlled propofol administration during anesthesia, initial dosing guidelines
are based on the typical subject, without taking into account the large inter-individual
variability. To manage this variability, most clinicians will start by giving a standard
dose, observes the therapeutic effect and will adapt the dose regimen. Although, "open-loop"
drug administration is clinically "standard-of-care", the efficiency of this decision
process highly depends on the expertise of the clinician, is very time consuming and might
result in a suboptimal therapy.

The study will be using patient with acute cholecystitis scheduled for laparoscopic
cholecystectomy surgery and the inclusion/exclusion criteria is described in the appropriate
sections. Potential subjects will be identified prior to their surgery based on meeting the
inclusion/exclusion criteria. The subject will be approached in the inpatient unit or
pre-operative holding area, a private area where curtains can be drawn to maintain privacy.
This is a place where patients are routinely examined and consented prior to surgery.. The
subject will be informed that participation or a lack of participation in the study does not
influence their treatment in any way. The subject will be informed that if they give
consent for participation in the study that they may withdraw consent at any time before
performance of the study. This withdrawal of consent may be given to the investigator in
oral or written form.

The Investigator will explain the study to the potential subject verbally, providing all
pertinent information (purpose, procedures, risks, benefits, alternatives to participation,
etc.), and allow the potential subject ample opportunity to ask questions. Following this
verbal explanation, the potential subject will be provided with a written consent form and
given at least one hour to consider whether or not to participate in the research. After
allowing the potential subject time to read the consent form, an Investigator listed on the
consent form will meet with the potential subject and answer any additional questions she/he
may have.

The subject will have been pre randomized to a study arm (Permuted block randomisation via
computer generated numbers) and will not be informed which study arm. The three study arms
are RL-TIVA (experimental), Manual TIVA, and INH-Sevo.

Premedication and Induction: Premedication with up to 0.05mg/kg IV midazolam

Prior to arrival in the operating room, a peripheral intravenous line will be inserted in a
large forearm vein in all patients and 500 ml of saline will be infused. This is required to
administer drugs and fluids during anesthesia and is routinely done in all patients. On
arrival in the operating room, vital signs (heart rate, non-invasive blood pressure, blood
oxygen saturation and end-tidal CO2) will be measured in all patients (standard of care
during anesthesia). The RL-TIVA group will also have a non-traumatic, commercially available
unilateral BIS electrode applied at the patient's forehead. This EEG sensor will be
connected to the BIS (Covidien, Mansfield, MA, USA) monitor to calculate the BIS.

All patients will undergo a standard IV induction using:

1mg/kg 1% lidocaine up to maximum of 100mg 100mcg fentanyl 2mg/kg propofol up to maximum of
200mg 0.6mg/kg rocuronium

Patients will be randomly allocated to standard volatile based anesthesia or BIS-guided
intravenous anesthesia administration. The protocol for each of the study arms is as
follows:

-RL-TIVA: Propofol, ketamine and sufentanil (PKS) administration will be done via a three
way stop cock connected directly to the IV catheter to minimize dead space volume. PKS
solution will contain total of 50ml. Propofol 10mg/ml, Ketamine 1mg/ml (will be omitted in
subsequent preparations after first 50ml), Sufentanil 0.25 mcg-ml. Drug will be administered
using a Harvard 33 syringe pump (The Harvard 33 Syringe pump has been used in human trials
in prior study at Stanford that is pending publication). This pump will be connected via a
RS 232 interface to the study computer running RL (reinforcement learning) control software.
This software platform collects real time vital signs and BIS values and steer the target
controlled infusion pumps and the closed-loop controllers.

Baseline vital signs, including BIS will be recorded for 2 minutes. During induction until 5
minutes after intubation, NIBP will be measured every minute. Thereafter, NIBP will be
measured at least every 3 minutes until the end of the case. The start of the baseline
measures will be considered as the "START CASE" moment.

IV anesthetic administration will start using the closed-loop system by setting the BIS
target at 45.

When required, optimization of the patients' positioning, disinfection and draping will
ensue. When ready, surgery will start.

During surgery, anesthesia will be maintained by propofol-ketamine-sufentanil via
closed-loop at a BIS target of 45.

- Manual TIVA: Manually titrated IV anesthetics are routinely done in the operating room
as an alternative to inhalational anesthetics. Propofol, ketamine and sufentanil (PKS)
administration will be done via a three way stop cock connected directly to the IV
catheter to minimize dead space volume. PKS solution will contain total of 50ml.
Propofol 10mg/ml, Ketamine 1mg/ml (will be omitted in subsequent preparations after
first 50ml), Sufentanil 0.25 mcg-ml. Drug will be administered using an Alaris
infusion pump titrated by the anesthesiologist based on blood pressure and heart-rate
as is traditionally done and is standard of care with intravenous anesthetics.

- INH-Sevo: After the patient is intubated Sevoflurane will be started and titrated to
between 0.8 and 1.5 MAC by the anesthesiologist. At end of surgery, as defined by
placement of surgical dressing, volatile anesthetic will be discontinued.

Wake up protocol will be the same for all three arms. Normocapnia will be maintained during
recovery by mechanical ventilation till spontaneous breathing is resumed. No decrease in the
Minute Ventilation is allowed during recovery. Moment of return of spontaneous breathing
will be recorded. Once spontaneous breathing is returned, patients will be asked by their
name to open their mouth. A positive response will be recorded and the trachea will be
extubated. Thereafter, patients will be transferred to the PACU. The parameters listed in
the appropriate section will be evaluated.

Data Collection: Subject data will be kept in 3 specific locations. A hard copy print out
will be maintained in a folder that will contain the eligibility criteria, consent form, and
source document. This will be stored in a locked file cabinet with limited access to the PI
and Co-Investigators. The electronic data will be stored on an encrypted flash drive kept in
the locked file cabinet and will be backed up on a secure encrypted Network folder that only
the PI and Co-Investigators will have authorization to access.

Statistical Analysis: A power analysis of the previously reported Stanford human volunteer
study data was performed in order to estimate appropriate sample sizes. To estimate
"worst-case" conditions, the measured parameter demonstrating greatest variation, MDPE, was
selected. Assuming comparison with a two-sample, two-tailed t-test and a p-value of 0.05, a
single-group sample size of 25 produced statistical power values of ~1.0. Given this size,
we can detect a 10% difference in MDPE under standard deviations of up to 7 and still
maintain power values > 0.85; thus, we selected n=25 for each of the three study groups,
yielding a total sample size of 75. We acknowledge that this sample size might prove to be
over-powered; however, intraoperative study is known to be challenging. For example, all of
the measured variables should not be expected to demonstrate normal distributions (a
critical assumption in the above power analysis), and we anticipate limited occurrence of
confounding influences, such as protocol deviations and interruptions in data collection.
Given the vagaries of intraoperative study, the chosen sample size of 75 patients seems
reasonable.

Descriptive statistics Categorical data:, sex, age, weight, height, induction times, times
to accurate control (time to reach target, overshoot in BIS), % of time for accurate control
and hemodynamic stability, recovery times, nausea, vomiting, sedation score, pain score, and
drug concentrations. Closed-loop control performance data (see below).

Continuous variables: BIS, heart rate, blood pressure, saturation, EtCO2 Univariate
analysis, Student's t-test or Mann-Whitney U-test will be used will be used to compare
numerical data and performance parameters.

Chi-squared will be used to analyse qualitative data. RMANOVA will be used to analyze the
continuous data.

Safety: An anesthesiologist or resident will be present for the entire duration of the
anesthetic as is standard of care. If at any time there is hardware or software failure, the
infusion can be disconnected and conventional volatile anesthetic can be rapidly instituted.
LIMITS OF THE CLOSED-LOOP (safety) : In the closed-loop control software, safety limits have
been installed.

Procedure for Analysis and Interpretation of the Safety Data: The monitoring entity will be
Benjamin Wallisch, MD. He will oversee the research participant's safety, monitor for
unanticipated problems involving risks to participants or others, and assure that such
events are reported to the IRB. Integrity and appropriate handling (confidentiality) of the
following data will be monitored: Demographic and morphometrics data, vital signs,
bispectral (BIS) index values, infusion pump flow rate, and recording of occurrence and
severity of drug side effects. Monitoring will occur after every study patient is enrolled.
Should unexpected adverse events occur. All effort will be made to identify the source
causing the event. Source identification may mandate the temporary halting of the study as
well as protocol adjustments (e.g. reduction of drug doses). Serious adverse events will be
reported by Benjamin Wallisch, MD within 2 business days. Serious adverse events will be
brought to the attention of the IRB within 24 hours.

Deviations to the study protocol or adverse events will be addressed by the IRB protocol. A
log will be kept of Adverse events and Protocol Deviation kept on the encrypted flash drive
and backed up on the encrypted network drive. The reporting of events will be as above
stated.

An annual progress report will be submitted to the IRB for review.

Inclusion Criteria:

- 18-65 years of age

- Body mass index lower or equal to 40 m2/kg

- Subjects must be able to comprehend spoken and written English or Spanish

Exclusion Criteria:

- Any type of psychiatric, neurological, or neuromuscular disorder

- Thyroid disease

- Alcohol consumption which exceeds 2 drinks per day and/or drug abuse.

- Allergy to study medication proposal, soy or egg proteins

- history of drug abuse

- chronic or acute use of opioids, or other medications affecting the central nervous
system

- pregnancy